3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Cancer of Lung in 5 studies
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gefitinib treatment induced EGFR arrest in the early endosome, and YC-1 treatment promoted delayed EGFR transport into the late endosome as well as receptor degradation." | 1.56 | YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells. ( Hu, H; Hu, MN; Li, JY; Miao, XK; Mou, LY; Xu, JJ; Yang, WL; Zhang, JY; Zhang, XW; Zhou, TX, 2020) |
| "Parkin downregulation in breast cancer cells promotes metastasis, which can be inhibited by targeting HIF-1α with RNA interference or the small-molecule inhibitor YC-1." | 1.46 | Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. ( Chen, J; Feng, Z; Gao, J; Gatza, ML; Haffty, BG; Hu, W; Huang, S; Khella, CA; Liu, J; Tomsky, K; White, E; Wu, H; Xia, D; Xie, H; Yue, X; Zhang, C; Zhao, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H | 1 |
| Miao, XK | 1 |
| Li, JY | 1 |
| Zhang, XW | 1 |
| Xu, JJ | 1 |
| Zhang, JY | 1 |
| Zhou, TX | 1 |
| Hu, MN | 1 |
| Yang, WL | 1 |
| Mou, LY | 1 |
| Shukuya, T | 1 |
| Oyanagi, J | 1 |
| Serizawa, M | 1 |
| Watanabe, M | 1 |
| Yamamoto, N | 1 |
| Koh, Y | 1 |
| Liu, J | 1 |
| Zhang, C | 1 |
| Zhao, Y | 1 |
| Yue, X | 1 |
| Wu, H | 1 |
| Huang, S | 1 |
| Chen, J | 1 |
| Tomsky, K | 1 |
| Xie, H | 1 |
| Khella, CA | 1 |
| Gatza, ML | 1 |
| Xia, D | 1 |
| Gao, J | 1 |
| White, E | 1 |
| Haffty, BG | 1 |
| Hu, W | 1 |
| Feng, Z | 1 |
| Ikezawa, Y | 1 |
| Sakakibara-Konishi, J | 1 |
| Mizugaki, H | 1 |
| Oizumi, S | 1 |
| Nishimura, M | 1 |
| Chen, CJ | 1 |
| Hsu, MH | 1 |
| Huang, LJ | 1 |
| Yamori, T | 1 |
| Chung, JG | 1 |
| Lee, FY | 1 |
| Teng, CM | 1 |
| Kuo, SC | 1 |
5 other studies available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Cancer of Lung
| Article | Year |
|---|---|
YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resista | 2020 |
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gene Knockd | 2020 |
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulation; Female; Heterografts; H | 2017 |
Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Hypoxia-Ind | 2017 |
Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; G1 Phase; Huma | 2008 |